Education
About Us
Working with TipRanks
Follow Us
Sight Sciences (SGHT)
NASDAQ:SGHT
SGHT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.29 - $8.45
Previous CloseN/A
Volume59.09K
Average Volume (3M)256.02K
Market Cap
$134.50M
Enterprise Value$233.87M
Total Cash (Recent Filing)-$21.24M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.04
Next Earnings
Mar 05, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding50,754,616
10 Day Avg. Volume303,676
30 Day Avg. Volume256,017
Standard Deviation0.29
R-Squared0.18
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.69
Price to Cash Flow (P/CF)92.90
P/FCF Ratio22.70
Enterprise Value/Market Cap1.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.38
Enterprise Value/Ebitda-5.05
Forecast
1Y Price Target
$4.00Price Target Upside50.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Sight Sciences News
PremiumPre-Earnings
Is SGHT a Buy, Before Earnings?
PremiumCompany Announcements
Sight Sciences Enhances Executive Compensation for 2025
---
Bulls Say, Bears Say
Bulls Say
Cash ManagementSGHT's cash position of ~$120M in hand is robust and affords it some flexibility on ongoing product launches.
Product Growth OpportunitiesThere are attractive growth opportunities in standalone MIGS and the Dry Eye business.
Bears Say
Regulatory ChallengesSGHT recently faced another obstacle regarding combination MIGS procedures, with five MACS issuing new LCDs rendering combination MIGS non-covered citing the lack of safety and efficacy data.
---
Ownership Overview
29.81% Insiders
5.52% Mutual Funds
18.63% Other Institutional Investors
39.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $2.29 and its highest was $8.45 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $134.50M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is Mar 05, 2025 which is tomorrow.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on Nov 07, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.208 by -$0.012.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.21.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 50,754,616 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.208. Following the earnings report the stock price went down -9.615%.
Which hedge fund is a major shareholder of Sight Sciences?
Currently, no hedge funds are holding shares in SGHT
---
Sight Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (50.94% Upside)
$4.00 (50.94% Upside)
Hedge Fund Trend
Decreased
By 11.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $181.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.52%
12-Months-Change
Fundamentals
Return on Equity
-45.36%
Trailing 12-Months
Asset Growth
-18.71%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company's product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company's non-surgical product portfolio consists of TearCare system which is commercially available for both ophthalmologists and optometrists.
---
SGHT Company Deck
---
SGHT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture, with some positive developments such as Medicare coverage confirmation and improved cash flow, but also significant challenges including revenue shortfalls and the impact of new LCDs on growth. The company's efforts to improve commercial execution and enhance organizational structures are positive steps forward, but the immediate financial challenges and market restrictions weigh heavily.Read More>---
SGHT Stock 12 Month Forecast
Average Price Target
$4.00
▲(50.94% Upside)
Technical Analysis
Best Analysts Covering SGHT
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
+1.46%
reiterated a buy rating 14 days ago
Copying Thomas Stephan's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of +1.46% per trade.
---